The study investigated the safety and efficacy of a sustained-release liposomal nanocarrier for latanoprost injected into the suprachoroidal space of the eye of Dutch rabbits. A single dose of 150 μl of a 2 mg/ml liposomal latanoprost formulation was administered into the suprachoroidal space. Intraocular pressure (IOP) decreased from baseline to 8 hours post-injection by 28% (5.1 ± 2.12 mmHg). On day 5, it reached a maximum reduction of 40% (7.2 ± 1.9 mmHg). A single dose of liposomal latanoprost lowered IOP for up to 56 days. This formulation may serve as a promising method of sustained drug delivery to the suprachoroidal space in the treatment of glaucoma. The eyes were clinically monitored for adverse events with no reported problems. Current glaucoma treatment depends on patient adherence and bioavailability after bypassing the ocular barriers.